Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Silmitasertib sodium salt (CX-4945 sodium salt) 是一种可口服的高度选择性 CK2抑制剂,对 CK2α 和 CK2α' 的 IC50值均为 1 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 295 | 现货 | ||
2 mg | ¥ 423 | 现货 | ||
5 mg | ¥ 693 | 现货 | ||
10 mg | ¥ 956 | 现货 | ||
25 mg | ¥ 1,880 | 现货 | ||
50 mg | ¥ 2,790 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 763 | 现货 |
产品描述 | Silmitasertib sodium salt (CX-4945 sodium salt) is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α). |
靶点活性 | CK2α:1 nM, CK2α':1 nM |
体外活性 | Silmitasertib induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathways[3]. Silmitasertib (CX-4945) resultes in cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalingand. The antiproliferative activity of Silmitasertib is correlated with expression levels of the CK2α catalytic subunit, attenuation of PI3K/Akt signaling[1]. Silmitasertib with PS-341 treatment prevents leukemic cells from engaging a functional UPR in order to buffer the PS-341-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expression[2]. |
体内活性 | Silmitasertib (CX-4945) (25 or 75 mg/kg, p.o.) is well tolerated. It showed robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models[1]. |
别名 | CX-4945 sodium salt |
分子量 | 371.75 |
分子式 | C19H11ClN3NaO2 |
CAS No. | 1309357-15-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 16.67 mg/mL (44.84 mM), sonification is recommended.
DMSO: 6 mg/mL (16.13 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.69 mL | 13.4499 mL | 26.8998 mL | 67.2495 mL |
5 mM | 0.538 mL | 2.69 mL | 5.38 mL | 13.4499 mL | |
10 mM | 0.269 mL | 1.345 mL | 2.69 mL | 6.7249 mL | |
H2O | 20 mM | 0.1345 mL | 0.6725 mL | 1.345 mL | 3.3625 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Silmitasertib sodium salt 1309357-15-0 Autophagy Metabolism Stem Cells Casein Kinase Silmitasertib CX4945 inhibit CX-4945 sodium salt Inhibitor CX-4945 sodium CX 4945 CX-4945 Silmitasertib sodium inhibitor